frog,
Let's hurdle that impasse and discuss the following:
"We are working to establish a technology platform, named ADMIXMAP, for the identification of functional human genes through the measurement of population structure. This system is currently for internal use solely by our scientists, and we do not generate revenue from any sales thereof. This platform of products will allow us to measure population structure as it was inherited from our ancestors. We can also measure certain effects of an individual's inherited traits in relationship to the general population of people - such as Native American, East Asian, sub-Saharan African and Indo-European and any combination of those four major population groups. We have identified characteristic markers for these population groups, and they are called Ancestry Information Markers or "AIMs". We believe we have identified these AIMs and associated them to specific traits that can be linked to an individual. For example, eye color, hair color and skin color are inherited traits, as is the ability of an individual's body metabolism to respond to a particular medication. By linking a drug's measurable response in an individual to our AIMs, we are able to predict whether or not an individual may or may not respond to a medication. There are many complex mathematical formulas involved in this analysis, and we plan to keep this technology and information closely guarded (patented when appropriate) and to sell our products and services to consumers, physicians and law enforcement."
What about the complex mathematical formulas they're keeping closely guarded. Are they among those you say a lot of big pharma scientists already have?
News 
Market Data 
Discover 
AI
